Research programme: AMPA antagonists - Egis Pharmaceuticals

Drug Profile

Research programme: AMPA antagonists - Egis Pharmaceuticals

Alternative Names: EGIS-10608; EGIS-10609; EGIS-10733; EGIS-11229

Latest Information Update: 14 Sep 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Egis Pharmaceuticals
  • Class Benzodiazepines
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Epilepsy; Neurological disorders; Stroke

Most Recent Events

  • 17 Oct 2007 Pharmacodynamics data from preclinical trials in Neurological disorders presented at the 20th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2007)
  • 21 Sep 2005 Preclinical trials in Stroke in Hungary (unspecified route)
  • 21 Sep 2005 Data presented at the 230th American Chemical Society National Meeting (230th-ACS-2005) have been added to the Neurological disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top